kstew updat baxter updat read-
 ant highlight coupl updat tonight includ quick summari start detail
section
first market close baxter provid busi updat note increas demand across number product
categori includ renal replac therapi iv solutions/pumps/set inject drug use icu baxter note
hire addit employe also donat million relief partner baxter plan releas result
april recal march compani held confer call provid result issu guidanc ithdrew
guidanc time expect constant currenc grow th hich includ slight benefit
acquisit rate equal eight compani busi mix less like advers impact
other med-tech group believ valuat alreadi reflect
 note coverag univers also sell infus pump set also sell limit number solut
agreement ith freseniu fre gy cover hassan al-w akeel eu medic technolog servic ho also sell
inject drug see detail
 ant highlight day depart human servic hh post amount remain
contract defens product act includ ithin coverag univers hillrom hillrom contract
price million ventil produc juli ith june contract price
million ventil produc june ith may june
 view amount hillrom posit give us addit confid outlook thesi maintain
overweight rate hillrom hillrom ill releas fiscal result may addit commentari
earlier today abbott announc launch lab-bas serolog test detect igg antibodi
 ould run architect instrument ill get updat abbott tomorrow earn call
 also ant highlight fda also issu tw compani ith emerg use author eua serolog test
ortho-clin diagnost subsidiari carlyl group gc cover jeffrey campbel broker asset manag
exchang hich anoth high-throughput serolog test run instrument lab
chembio diagnost system cemi cover hich point-of-car test provid result igm igg level
finger stick minut eua author use lab certifi clia perform moder high
complex test ever fda emerg guidanc compani distribut serolog test ithout eua see march updat
page provid test done lab healthcar orker point care chembio announc
start ship march prior eua note collabor ith biomedom privat cover
launch point-of-car igm-igg rapid test also use test fir antibodi ithin minut fingerstick
agreement also announc march
april fda note test develop ho notifi agenc serolog test avail
use list compani notifi fda test detail
ortho-clin diagnost chembio diagnost system biomedom coverag barclay research inform
compani provid inform purpos invest recommend barclay research
first compani receiv eua cellex privat cover april note fda allow compani ith serolog test
distribut test ithout obtain approv provid meet certain standard make certain disclosur
serolog test check inform deep dive examin near potenti long-term
rippl effect report colleagu meehan also host call yesterday ith expert serolog test
read takeaw ay barclay life scienc tool dx serolog test expert call takeaw ay
detail
alway stay safe stay healthi well kind feel free reach
market close baxter announc updat busi note see increas demand certain product
relat specif see increas demand
acut therapi product prismax prismaflex patient ith suffer acut kidney injuri help
renal replac therapi fyi acut therapi repres baxter global sale
iv infus system iv set baxter note see demand solut consum note
particular mini-bag drug-deliveri system fyi medic deliveri sale account baxter global sale
inject drug use icu sale account total sale exclud cyclo brevi
total sale ever busi also includ anesthesia hich believ ould advers affect due
reduc elect procedur ell drug compound thu perhap exposur ould like total sale
 note deep div exam ine near potenti long-term rippl effect report
follow ing manufactur
product competitor
baxter us us primarili pump set limit iv
solut relationship ith freseniu freseniu medic fme gr pump outsid unit
state freseniu fre gy cover hassan al akeel iv drug icu care
cover barclay
hh announc contract addit manufactur
last eek depart human servic announc first contract defens product act ith gener
motor gm us cover brian johnson philip phia na cover hassan al-w akeel
 note ventil full-featur other hich explain price differenti
gener electr ge cover julian mitchel total contract price million ventil
produc june includ product ventil may ventil june averag price per
ventil
hillrom total contract price million ventil produc juli ith june
averag price per ventil includ amount revenu model present thu could
repres upsid forecast and/or help off-set revenu contract could push
total contract price million ventil produc june includ
ventil may ventil june averag price per ventil note see higher
level demand ventil across board global low er govern contract view ed neg
cover total contract price million ventil produc juli
includ ventil may ventil june averag price per ventil
vyair privat cover total contract price million ventil produc june
includ ventil may ventil june averag price per ventil
hamilton privat total contract price million ventil produc may includ
product ventil may ventil may averag price per ventil hamilton
relationship ith ge
zoll subsidiari asahi kasei jt cover total contract price million ventil
produc juli includ ventil may ventil june averag price per ventil
initi tw contract defens product act hich ere invok presid trump ere announc april
depart human servic hh ventil ill rout strateg nation stockpil sn
deploy locat need
gener motor gm cover brian johnson total contract price million ventil
deliv sn end august first deliveri ventil schedul june averag price
per ventil
philip phia na cover hassan al-wakeel total contract price million deliveri
ventil sn end decemb includ deliveri ventil end may
averag price per ventil hassan al-w akeel note philip ventil contract ith us govern
inform
abbott announc launch lab-bas serolog test detect igg antibodi igg indic hether
someon previous infect ith thought ould appear day infect test ill
initi avail architect instrument instrument us laboratori
abbott note instrument run test per hour abbott expect ship close million test eek
custom expect ship million test total april compani ramp million test us june
beyond run new alin system abbott also plan expand test detect antibodi igm near futur
understand assay price around per test abbott plan file eua submiss ith fda abbott
ship ithout eua plan ce mark ivd direct eu
ocd grant eua antibodi assay vitro total antibodi test indic detect total antibodi includ
igg igm human serum plasma specimen test run vitro xt integr system
vitro immunodiagnost vitro integr soon ill avail vitro eci/eciq
immunodiagnost system ocd comment vitro system instal hospit refer lab
us instrument run test per hour
ocd initi launch test limit basi begin april fda updat notif pathw ay compani plan
full product come eek expect manufactur sever million test next month ith rapid
dpp serolog point-of-car test analyz indic qualit detect
differenti igm igg antibodi serum plasma venou hole blood fingerstick hole blood system provid
numer read igm igg level ithin minut
compani micro reader micro reader analyz compat ith test compani announc us launch
test march fda updat notif pathw ay partner ith lumiradx privat cover scale
base market demand
emerg use test limit author laboratori certifi perform moder high complex test
serolog test
serolog test measur hether antibodi present amount antibodi person blood antibodi may
initi present earli thu serolog test use diagnos may help tool determin ho
infect past develop immun
igm first antibodi made bodi found mainli blood lymph fluid typic produc rapidli
infect igm typic temporari disappear usual eek product igg abundantli found
antibodi bodi found lymph blood intestin last longer period
know dont know antibodi
studi includ confirm probabl case china median durat igm detect day
interquartil rang hile igg detect median day interquartil rang symptom onset
guo li ph et al profil earli humor respons diagnos novel coronaviru diseas clinic infecti diseas
label indic serolog test indic preliminari data show median incub period
approxim day may rang day
april pre-print peer-review ed publish medrxiv titl neutral antibodi respons
recov patient cohort implic fan et al neutral antibodi respons covid-
recov patient cohort implic medrxiv neutral antibodi nab import clear viru
import part immun respons protect treatment viral diseas studi plasma
collect recov patient ith mild symptom none patient ere admit icu median
length hospit stay day median diseas durat day investig found recov
patient gener low titer specif nab patient studi titer ere low
detect level medium-low level medium-high high level nab investig found
 ere variat titer nab depend age group ith elderli patient like induc higher level
new viru long-term data determin long immun last data sar outbreak show ed titer
igg neutral antibodi peak month infect ith subsequ declin least year infect
regard reinfect potenti accord recent updat publish jama april hile evid reinfect
evolv current data experi previou virus ithout substanti season mutat support hypothesi
patient becom reinfect ith viru least mani month year initi infect sb malani del rio
pandem us clinic updat jama publish on-line april
serolog test manufactur lot
march fda issu updat polici diagnost test ithin updat polici allow ed develop
certain serolog test market use test determin test ere accur reliabl ithout prior fda review
fda note serolog test less complex molecular test use sole identifi antibodi viru
provid adequ disclosur inform provid note thing test review ed fda neg
result rule infect follow -up test ith molecular test consid etc fda
intend object develop distribut test
april fda grant first eua serolog test intend use clinic lab cellex ho ork ith mayo
clinic addit eua ere grant april ortho-clin diagnost chembio diagnost system abbott ork
tow ard submit eua
april fda note ere test develop ho notifi agenc serolog test avail
commerci manufactur laboratori list notifi fda valid offer serolog test
set forth section iv fda polici diagnost test coronaviru sourc list fda ebsit
 believ illustr crow ded field serolog test ould surpris see fda start regul
area given emerg concern around accuraci serolog test
univers minnesota advanc research diagnost laboratori
igg use architect
getein biotech inc one step test novel coronaviru igm/igg antibodi colloid gold
maccura biotechnolog co ltd sever acut respiratori syndrom coronaviru igm/igg antibodi assay kit
zhuhai livzon diagnost inc diagnost kit igm/igg antibodi coronaviru colloid gold
click titl access note
believ great read deep dive examin near potenti long-term rippl effect
think investor visual novel coronaviru giant boulder throw lake creat big initi
splash upon entri rippl ill seen felt reach far shore time initi focu
investor commun big splash creat near-term effect import question difficult
answ er hat effect rippl hat long-term impact healthcar industri
 holeprovid physician patient insur cours med-tech compani report aim
 healthcar physician survey reduc offic visit procedur across multipl specialti
barclay global healthcar survey physician state across differ sub-specialti includ
gastroenterolog endocrinolog dermatolog neurolog hemo-oncolog rheumatolog evalu impact
practic trend particularli offic volum elect procedur prescript pattern nearli physician report
signific declin patient offic visit averag visit around primari reason behind
declin appear patient cancel visit telehealth appoint significantli perhap enough off-set
declin in-person visit major physician indic facil hospit asc offices/surgi-
center implement polici cancel elect procedur led signific reduct surgeri report
list common elect procedur specialti cancel usual suspect like knee hip replac
arthroscopi radiofrequ ablat nerv block spinal fusion stent etc ere list think list greater
might think includ procedur like valv replac tavr laa prevent icd pacemak
cabg peripher intervent endoscopi prostatectomi db also talk implic
 medic suppli devic put take isrg-get readi arn flag insid
reportw review med-tech takeaw ay barclay global healthcar confer discuss american
colleg surgeon surgeon gener recommend cancel elect procedur review state health system
hospit taken action limit elect procedur action relev medic devic includ
commentari regard build new bed review hat elect procedur discuss product mix
compani review hat product could use effort compani manufactur product
feedback kol call ednesday march barclay equiti research global healthcar team
host expert confer call ith senior epidemiologist dr arnold monto md note summar takeaw ay
hill-rom hold inc upgrad overw eight readi abl assist ith estim least
hillrom sale rental bed legaci elch allyn product thermometri patient monitor blood
pressur physic examin product could use help triag assess monitor aid treatment
patient hillrom also recent acquir hich non-invas ventil anoth hillrom
busi acut care frame hich includ icu bed mani hospit state cite shortag
kstew updat aim doubl capac global demand reiter ow reiter
overw eight rate hillrom market close hillrom announc global demand sever critic product
grow substanti ork significantli ramp product ith goal doubl capac
follow ing area respiratori health icu med-surg smart bed patient monitor diagnost
kstew updat isgr prelim vent contract updat cover announc
preliminari result similar mani med-tech compani ithdrew guidanc cite believ
provid read-thru coverag univers also ant provid addit ventil updat
 ell updat put depart human servic
kstew updat trump invok dpa vent ork sign contract /mdt other
 hite hous updat on-going ant pass-along one quick updat start eekend
trump note invok defens product act ventil ork ith sever manufactur includ
hillrom view new posit compani reiter overw eight rate
kstew updat sunday rundow fda issu guidanc doc ventil focu vent edit
give run-dow eekend new provid run-dow ventil provid review fda guidanc
document issu eekend list major manufactur ventil suppli
kstew updat count eather cdc outlin return ork guidelin present
find nation academi scienc engin medicin committe find relat
temperatur humid potenti season
kstew updat ny apex vent updat abt dx airtim presid trump other
updat discuss updat ny state trend updat hite hous press
brief ventil ell abbott test
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog believ stock
maintain premium multipl given top line bottom line grow th prospect pt appli multipl ep
risk may imped achiev barclay research valuat price abbott signific
exposur emerg market intern broadli thu chang fx rate could pressur sale ep result new
product central posit view approv adopt new product therefor anoth risk risk includ
healthcar reform effort medicar reimburs chang product recal fda arn letter
govern regulatori action libr signific driver grow th chang trajectori key risk factor
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
valuat methodolog pt appli target pe ep estim appli premium valuat give
credit compani balanc sheet strength
risk may imped achiev barclay research valuat price new product import
baxter grow th outlook therefor approv uptak new product key risk factor gener competit particularli
cyclo brevibloc could pressur earn and/or extent pressur less expect favor impact fx rate
stronger us dollar could also pressur baxter sale earn outlook risk includ signific reimburs
chang fda govern action also view abil baxter obtain tech-add-on dialyz risk
factor believ market current price
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
co usd equal eight/neutr a/cd/ce/d/e/j/k/l/m/n
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli multipl calendar ep
risk may imped achiev barclay research valuat price upsid risk factor
extent becton success integr bard see greater expect revenue/cost synergi shorter time period
resolv alari pump issu greater success ith new product nside fx stronger us dollar commod cost
could greater headw ind risk factor includ time success new product delay resolv alari pump
issu increas competit key product drug-coat balloon infus pump signific chang reimburs
fda govern action
rate price target histori
co
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli price-to-earnings multipl calendar year ep
risk may imped achiev barclay research valuat price upsid new product drive
acceler sale ep grow th accret acquisit continu favor hospit capital-expenditure environ
nside less favor trend hospit capital-expenditure delay due slow er uptak new product strengthen us
dollar higher tax rate risk includ signific reimburs chang fda product approv time competit
pressur fda govern action
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli target pe calendar ep estim grow th profil improv expect pe
expand closer peer
risk may imped achiev barclay research valuat price nside risk includ fx rate
strengthen us dollar hich could pressur earn stock perform new product key futur success
compani thu extent compani unabl receiv fda approv could advers impact futur
outlook product includ compani surgic robot platform minim futur iter continu blood glucos
monitor devic transcathet valv system upsid greater success ith new product margin expans risk
includ signific reimburs chang competit pressur product failur fda govern action
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
unless otherw ise indic price sourc bloomberg reflect close price relev trade market hich
may last avail price time public
